Doseology expands into US retail market


VERNON, BC, July 14, 2022 /CNW/ – Dosology Sciences Inc. (CSE: MOOD) (OTCQB: DOSEF) (FSE: VU7) (“Doseology” or the “Company”), a life sciences company focused on mental health and wellness, is delighted to announce that ‘She signed a sales management agreement with Alternative Sales Management to act as the company’s National Sales Manager for its expansion into United States retail market.

Gary Gobeli, President of Alternative Sales Management, is a qualified master broker and senior executive within the natural and organic industry. With over three decades of experience, Gobeli brings a set of skills and experiences that have led to success for him and his partners – he has been a distributor and manufacturer’s representative, owned a brokerage firm, and served as director of regional and national sales. for top brands like Atkins and Symbiotics. He is an expert in assessing market trends, developing and implementing goal-oriented strategies, networking with manufacturers and distributors, and bringing start-ups and companies to market. major brands.

The commitment of Alternative Sales Management comes at a good time, as the market for functional mushrooms continues to grow in United States in 2022. Notably, Tastewise predicts continued interest in functional foods with 33% more consumers treating food as medicine in 2022 compared to 2020.

The benefits of functional mushrooms have been the subject of intense study in recent years. For example, a 2021 study by Penn State College of Medicine found that consistently eating mushrooms reduced the risk of depression. This effect is attributed to certain edible mushrooms, such as lion’s mane, which have the potential to enhance neuron production and survival, which may help prevent neuropsychiatric disorders, such as depression. There are thousands of other studies that highlight the benefits of these mushrooms.

Other projections for the functional mushrooms market include a compound annual growth rate of 8.44% from an expected increase in demand for functional foods and nutraceuticals from 2021 to 2026. Additionally, the global market should reach US$44.8 billion by 2027.

Doseology will capitalize on this increased interest with its expansion into the important United States retail market. The company plans to partner with specialist supplement distributors and target independent retailers and specialty chains to establish a solid foundation before moving to mass retailers.

The current functional mushroom products in Doseology’s US line are:

  • Wake: Blend of lion’s mane mushroom fruiting bodies, yerba mate, and vitamins B6 and B12 to promote wakefulness and support cognitive performance (tincture, 28 servings).
  • Raising: Blend of Lion’s Mane Mushroom Fruiting Bodies, Ginger Root, and Vitamin B3 to Uplift Mood and Improve Cognitive Clarity (tincture, 28 servings).
  • Asset: Fruiting Bodies Blend of Cordyceps Mushrooms and Rhodiola to Promote Energy, Improve Physical Performance and Relieve Mental Fatigue (tincture, 28 servings).
  • Retrieve: Blend of shiitake and turmeric fruit bodies to provide the body with powerful antioxidants to boost and support immunity (tincture, 28 servings).
  • Rest: Blend of reishi mushroom fruiting bodies, German chamomile and melatonin to promote relaxation and sleepiness (tincture, 28 servings).
  • Think: Blend of lion’s mane mushroom, reishi, shiitake and chaga fruiting bodies, yerba mate, rhodiola, choline, organic cocoa powder and monk fruit extract. Super Mushroom Cognitive Complex is formulated to give the brain the building blocks it needs to optimize cognitive function and to improve focus and alertness. (cognitive complex powder, 30 servings).
  • Defend: Blend of lion’s mane, reishi, shiitake, turkey tail, chaga, maitake, royal sun agaricus, white button and black fungus fruiting bodies along with cordyceps mycelium. These 10-in-1 super mushroom capsules are formulated to provide daily immune support (mushroom capsules, 30 servings).

For sales inquiries contact: [email protected]

On behalf of the Board of Directors

Ralph Olson
Chief executive officer
Dosology Sciences Inc.

Doseology Sciences Inc. is building a progressive brand focused on mental health and wellness through cultivation, extraction, and innovative nutraceuticals and pharmaceuticals. Doseology aims to make a significant impact on the mental health pandemic by using and developing functional mushrooms and plant-derived medicines. With a vertically integrated approach, Doseology intends to process and distribute products through its facilities in Vernon, British Columbia, in accordance with applicable laws to ensure safe and high-quality production. Doseology’s medicinal mushroom products, including tinctures, powders and supplements, are available at


Forward-looking statements

This press release contains statements that constitute “forward-looking information” within the meaning of applicable securities laws. Forward-looking information is often identified by the words “may”, “could”, “should”, “will”, “intend”, “plan”, “anticipate”, “believe”, “estimate”, ” wait” or similar expressions. Readers are cautioned that forward-looking information is not based on historical fact but rather reflects the Company’s management’s expectations, estimates or projections regarding the business of future results or events of the Company based on opinions, assumptions and management’s estimates believed to be reasonable at the date the statements are made. Although the Company believes that the expectations reflected in such forward-looking information are reasonable, such information involves risks and uncertainties, and undue reliance should not be placed on such information, as unknown or unpredictable factors could have material adverse effects on future results, performance, or achievements. Among the key factors that could cause actual results to differ materially from those projected in the forward-looking information are the following: changes in general economic, business and political conditions, including changes in financial markets; declines in prevailing prices for products in the markets in which the Company operates; adverse changes in applicable laws or adverse changes in the application or enforcement of applicable laws; regulations and enforcement priorities of governmental authorities; compliance with government regulations and related costs; and other risks described in the Company’s prospectus. Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking information prove incorrect, actual results may differ materially from those described herein as anticipated, planned, anticipated, believed, estimated or expected. Although the Company has attempted to identify important risks, uncertainties and factors that could cause actual results to differ materially, there may be others that cause results not to be those anticipated, estimated or planned. The Company does not intend and undertakes no obligation to update this forward-looking information, except as otherwise required by applicable law. For further information, investors should consult the documents filed by the Company which are available at SEDAR.

No securities regulatory authority has approved or disapproved of the contents of this press release. The securities of the Company have not been and will not be registered under the United States Securities Act of 1933, as amended, or any state securities law, and may not be offered or sold in United Statesor to or for the account or benefit of any person in United States, lack of registration or applicable exemption from registration requirements. This press release does not constitute an offer to sell or the solicitation of an offer to buy securities of United Statesor in any other jurisdiction in which such offer, solicitation or sale would be unlawful.

Industry data

This press release includes market, industry and economic data that has been obtained from various publicly available sources and other sources believed to be true by the Company. Although the Company believes it to be reliable, the Company has not independently verified any of the data from third-party sources referenced in this press release, nor analyzed or verified the underlying reports relied upon. are based on or to which these sources refer, nor verified the underlying economic and other assumptions on which these sources are based. The Company believes that its market, sector and economic data are accurate and that its estimates and assumptions are reasonable, but there is no guarantee of their accuracy or completeness. The accuracy and completeness of market, industry and economic data used in this press release is not guaranteed and the Company makes no representations as to the accuracy or completeness of such information. .

CSE does not accept responsibility for the adequacy or accuracy of this release.

SOURCE Dosology Sciences inc.

For more information: Investor Relations: [email protected]; General Information: [email protected]Phone: 236-349-0064


About Author

Comments are closed.